Liposomes versus metallic nanostructures: differences in the process of knowledge translation in cancer

David Fajardo-Ortiz1, Luis Duran1, Laura Moreno1

  • 1Faculty of Medicine of the National Autonomous University of Mexico, Mexico City, Mexico.

Insights

Knowledge translation in cancer nanotechnology reveals distinct pathways for liposomes and metallic nanostructures (MNs). Liposomal drug delivery shows organized translation, while MN research remains in early stages, focusing on imaging and therapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Nanotechnology offers promising therapeutic strategies for cancer treatment.
  • Liposomes and metallic nanostructures (MNs) are key nanocarriers in oncology research.
  • Understanding knowledge translation is crucial for advancing nanomedicine.

Purpose of the Study:

  • To map the knowledge translation process for liposomes and metallic nanostructures (MNs) in cancer research.
  • To analyze citation networks and text mining data for insights into research trends.
  • To identify differences in knowledge translation between liposome and MN applications.

Main Methods:

  • Structural analysis of citation networks.
  • Text mining utilizing controlled vocabularies.
  • Identification of subnetworks (invisible colleges) within research fields.

Main Results:

  • Liposome research shows distinct subnetworks for nanopharmacology, hyperthermia, and gene therapy.
  • Organized knowledge translation in liposomes is primarily linked to liposomal doxorubicin formulations.
  • Metallic nanostructures (MNs) research lacks clear therapeutic strategy differentiation and remains in basic research.
  • MN research is heavily focused on combined molecular imaging and photothermal therapy.

Conclusions:

  • Knowledge translation pathways differ significantly between liposomes and MNs in cancer nanotechnology.
  • Liposomal drug delivery demonstrates a more mature translation process compared to MNs.
  • Further research is needed to advance the translation of MN-based cancer therapies.